Most Read Articles
Stephen Padilla, 05 Jan 2018
The addition of an antihypertensive drug from a new class to a patient’s regimen results in huge decreases in systolic blood pressure (SBP) and major cardiovascular (CV) events among those at high risk for CV events but without diabetes, suggests a recent study. Its effects on SBP remain large and similar in magnitude across all levels of baseline drug use and all subgroups of patients.
Pearl Toh, 4 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Yesterday
The risk of stroke and subsequent mortality is significantly elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), a recent study has shown.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.

Perioperative statin reduces postoperative atrial fibrillation but not acute kidney injury

Tristan Manalac
12 Sep 2017
Canakinumab might be another alternative for statins, which have been the ‘go-to‘ medication for patients with heart attacks.

Perioperative statin use prevents postoperative atrial fibrillation (POAF) but not myocardial infarction (MI) and acute kidney injury (AKI), according to a recent meta-analysis.

“[P]erioperative statin use is useful in preventing POAF after cardiac surgery, particularly in patients with [coronary artery bypass grafts (CABG)], and ameliorat[ing] inflammation,” said researchers.

“Therefore, statin should be given to patients undergoing CABG but not valve surgery for preventing POAF,” they continued.

The current meta-analysis included RCTs that compared POAF, AKI and MI outcomes in cardiac surgery patients treated with perioperative statins or with placebo or routine medications. The databases of PubMed, Cochrane Library and Embase were accessed.

Analysis of pooled data from 18 eligible randomized controlled trials (RCTs; n=3,995) showed that the risk of POAF was significantly lower with perioperative statin use (relative risk [RR], 0.69; 95 percent CI, 0.56 to 0.86; p=0.001). [Sci Rep 2017;7:10091]

In contrast, nine studies (n=3,214) showed that the risk of postoperative AKI was unaffected by the use of perioperative statin (RR, 0.98; 0.70 to 1.35; p=0.884), while 14 studies showed that MI risk was also unaffected by perioperative statin use (RR, 0.84; 0.58 to 1.23; p=0.765).

“[T]he decreased incidence of POAF might be owing to the anti-inflammation and antioxidant [properties] of statin,” the researchers explained.

Because the kidney is very vulnerable to severe injury, the anti-inflammation and antioxidant properties of statins may not be enough to significantly improve AKI, the researchers continued.

“Additionally, the high susceptivity of POAF on inflammation and oxidization might also be involved in the inconsistent finding between AKI and POAF,” they noted.

In terms of secondary clinical outcomes, perioperative statin use did not exert significant effects on mortality (RR, 1.13; 0.56 to 2.27; p=0.740), duration of ventilation (standard mean difference [SMD], -0.01; -0.44 to 0.42; p=0.967), length of stay in the intensive care unit (SMD, 0; -0.12 to 0.12; p=0.987) or length of hospital stay (SMD, -0.18; -0.37 to 0; p=0.051).

In contrast, peak concentrations of C-reactive protein (SMD, -0.43; -0.71 to -0.14; p=0.003) and cardiac troponin (SMD, -0.75; -1.04 to -0.47; p<0.001) were significantly reduced as a result of perioperative statin use.

Statins are drugs that lower cholestenone and stabilize atherosclerotic plaques, both of which are hallmarks of coronary artery disease. The drug “has been reported to contribute toward the stabilization of transmembrane ion channel, modification the extracellular matrix remodelling, and has effect of anti-inflammation and anti-oxidant,” according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Stephen Padilla, 05 Jan 2018
The addition of an antihypertensive drug from a new class to a patient’s regimen results in huge decreases in systolic blood pressure (SBP) and major cardiovascular (CV) events among those at high risk for CV events but without diabetes, suggests a recent study. Its effects on SBP remain large and similar in magnitude across all levels of baseline drug use and all subgroups of patients.
Pearl Toh, 4 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Yesterday
The risk of stroke and subsequent mortality is significantly elevated in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), a recent study has shown.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.